PGP and cancer: Cancer patients undergoing doxorubicin treatment demonstrated an upregulation of P-gp that had a very broad substrate spectrum, allowing it to mediate the export of a plethora of anticancer agents, including docetaxel, vinblastine, paclitaxel, lovastatin, atorvastatin, etoposide, vincristine, daunorubicin, digitoxin, digoxin, cyclosporine, and gefitinib, among many others[37].